How Statins Work
Statins are HMG-CoA reductase inhibitors—drugs that block a key enzyme in the cholesterol synthesis pathway. Here's the mechanism:
- HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol synthesis
- Statins bind competitively to this enzyme, reducing cholesterol production in liver cells
- LDL receptors increase on hepatocytes to compensate, pulling more LDL from circulation
- Net effect: LDL cholesterol drops 30-50%, triglycerides drop 20-30%, HDL modestly increases
Beyond cholesterol lowering, statins have pleiotropic effects: they reduce inflammation, stabilize atherosclerotic plaques, improve endothelial function, and reduce thrombotic tendency. These non-lipid effects may contribute to cardiovascular benefit independent of cholesterol lowering.
Key insight: Statins lower LDL and ApoB (apolipoprotein B, the structural protein of atherogenic particles). The effect is dose-dependent and consistent across statin types, though some statins (atorvastatin, rosuvastatin) are more potent than others (pravastatin, simvastatin).
Common and Uncommon Side Effects
Muscle-Related Side Effects
Myalgia (muscle pain without elevated CK): Occurs in 5-10% of statin users. Muscle aching, soreness, or weakness appears during treatment and resolves upon cessation. Most are mild to moderate.
Myopathy (muscle damage with elevated CK): Rare (<0.1%). Elevated creatine kinase (CK) indicates muscle fiber breakdown. This can progress to rhabdomyolysis (severe muscle breakdown) in extreme cases, though true statin-induced rhabdomyolysis is exceedingly rare.
Risk factors for muscle toxicity:
- High statin doses (especially 40 mg simvastatin, 80 mg atorvastatin)
- Drug interactions (certain antibiotics, antifungals, protease inhibitors)
- Advanced age
- Renal impairment
- Hypothyroidism (impairs clearance)
- Genetic polymorphisms in drug-metabolizing enzymes
Management: If myalgia occurs, stop the statin, retest CK, and consider rechallenge at lower dose or switch to a different statin. Some patients tolerate pravastatin better than atorvastatin, or benefit from taking statins every other day.
Liver Enzyme Elevation
Transaminase elevation (AST, ALT >3x upper limit of normal) occurs in ~1-2% of users. Usually asymptomatic and resolves within weeks. Rarely progresses to hepatotoxicity; monitoring with ALT at baseline and 6-8 weeks is standard.
Management: Retest if elevated; most normalize without stopping. If persistently elevated (>3x ULN) or accompanied by symptoms (jaundice, abdominal pain), discontinue and investigate liver disease.
Diabetes Risk
Statins may modestly increase type 2 diabetes risk (~13% relative increase in some trials). Absolute risk is low, and the cardiovascular benefit in high-risk patients often outweighs this risk. Mechanism is unclear but may involve impaired insulin secretion or slight weight gain.
Monitoring: Annual fasting glucose or HbA1c if risk factors (family history, obesity, prediabetes).
Cognitive and Memory Complaints
Rare but documented: some patients report memory problems, confusion, or concentration difficulty. These are often subjective, and objective cognitive testing rarely shows deficits. Usually reversible upon discontinuation. Incidence is likely overstated due to nocebo effect (expectation of harm).
Sexual Dysfunction
Some men report erectile dysfunction or reduced libido. Mechanism unknown; causation is debated. Likely partly nocebo effect. Prevalence is similar to placebo in randomized trials.
Other Side Effects (Rare)
- Tendon rupture (extremely rare; association unclear)
- Immune-mediated myositis (very rare; can be severe)
- Peripheral neuropathy (uncommon; usually reversible)
- Hemorrhagic stroke (slight increased risk at high doses in some populations)
Who Benefits Most from Statins
Secondary Prevention: Clear Benefit
If you have a history of heart attack, ischemic stroke, peripheral artery disease, or coronary revascularization, statins reduce recurrent events by 25-30%. The benefit is consistent across ages, sexes, and baseline LDL levels. Start or continue statins unless intolerant.
Primary Prevention: More Nuanced
For people without prior cardiovascular disease, benefit depends on risk:
Strong indication:
- ApoB ≥130 mg/dL (reflects burden of atherogenic particles)
- Lp(a) ≥50 mg/dL (genetic risk factor for thrombosis and premature CAD)
- Coronary Artery Calcification (CAC) score ≥400 (indicates substantial atherosclerotic burden)
- 10-year CVD risk ≥15% (traditional risk calculator)
- Age 40-75 with diabetes
Consider:
- Multiple borderline risk factors (hypertension, prediabetes, overweight, family history, smoking)
- Age >75 with controlled risk factors
Do not start:
- Age <40 without other major risk factors
- CAC score of 0 (zero calcification indicates low 10-year event risk; may not need statins even if elevated LDL)
- Low absolute risk (<7% 10-year CVD risk) and no family history of early MI
Key insight: Zero CAC is powerful reassurance. A 55-year-old with high LDL but zero CAC has <2% 10-year MI risk and may not benefit from statins. Conversely, someone with CAC >400 needs statins regardless of baseline LDL because plaque is already present.
Side Effects vs. Nocebo Effect
Statin side effects are real, but nocebo effect (harm from expectation) inflates perceived incidence. Studies find:
- In randomized trials, myalgia occurs in ~5% on statins and ~5% on placebo
- Stopping a statin for "side effects" then restarting it later often tolerates fine if patient is blinded to which arm they're on
- Switching to a different statin often works in patients convinced the previous statin harmed them
The takeaway: Don't dismiss your symptoms, but recognize that expectation shapes perception. If myalgia starts within days of beginning a statin, it's likely nocebo; real statin myopathy develops over weeks to months. A structured rechallenge with objective testing (CK) helps clarify.
Monitoring: What Bloodwork to Track
If on a statin, annual or baseline monitoring includes:
| Test | Baseline | During Treatment | Why |
|---|---|---|---|
| LDL, HDL, Triglycerides | Yes | Every 6-12 months | Assess efficacy and response |
| ApoB | Recommended | As needed | Better than LDL for risk |
| ALT (liver enzyme) | Yes | 6-8 weeks, then annually | Detect hepatotoxicity |
| CK (creatine kinase) | If symptomatic | Only if muscle pain occurs | Assess myopathy vs. myalgia |
| Fasting glucose or HbA1c | If prediabetic | Annually | Monitor diabetes risk |
| Hematocrit | No | No | Not affected by statins |
Don't routinely order CK if asymptomatic; elevated CK without symptoms is often benign variation.
Alternatives to Statins (or Adjuncts)
If statins are intolerant or insufficient:
PCSK9 Inhibitors
Mechanism: PCSK9 proteins degrade LDL receptors. PCSK9 inhibitors (alirocumab, evolocumab) prevent this, increasing LDL clearance.
Effect: Additional 50% LDL reduction beyond statin.
Downsides: Expensive; requires injections.
Indication: Familial hypercholesterolemia, statin intolerance, or LDL goal not met on statin.
Ezetimibe
Mechanism: Blocks cholesterol absorption in the intestine.
Effect: Additional 15-20% LDL reduction if combined with statin.
Downsides: Modest effect; less data on cardiovascular benefit alone.
Use: Add to statin if LDL goal not met.
Bempedoic Acid
Mechanism: Inhibits urate and cholesterol synthesis.
Effect: 15-20% LDL reduction; also lowers uric acid (helpful if gout).
Data: Newer agent; some studies suggest cardiovascular benefit, others less clear.
Use: Emerging alternative for statin-intolerant patients.
Inclisiran
Mechanism: siRNA targeting PCSK9 production in liver.
Effect: Sustained 50% LDL reduction.
Downsides: Very new; limited long-term data.
Lifestyle Optimization
Diet (Mediterranean, DASH, portfolio diet), exercise, weight loss, and smoking cessation lower LDL and CVD risk. These work synergistically with statins but rarely eliminate need for them in high-risk individuals.
When to Reconsider or Stop Statins
Don't stop abruptly without discussing with your doctor, but reconsider if:
- Secondary prevention + unbearable myalgia + negative CK: Try dose reduction or switch
- Primary prevention + zero CAC + LDL controlled: May stop if very low risk
- Age >80 + no prior CVD + low absolute risk: Benefit-risk ratio less favorable
- New diagnosis of liver disease: Contraindicated
- Severe myopathy (CK >10x ULN): Stop immediately
Your cardiologist can help weigh risks and benefits specific to your situation.
How Merios Helps
Merios interprets your lipid panel (LDL, HDL, triglycerides) and explains what your numbers mean in the context of your overall cardiovascular risk. We help you understand whether statins are right for you based on your complete picture.
Upload your blood test to Merios →
This article is for educational purposes only and should not replace professional medical advice. Never stop or start statins without consulting your cardiologist or primary care physician. Statin decisions depend on individual risk factors that only a physician can assess.